医用纳米控释系统的研究进展

3(,300072),,,,,,,:;;;;:R318.080(Nanoparticles)(Nanocapsules),10nm500nm,(),,,2,,;,;2[13];,;(1),;(2);(3),,;(4),;(5),;(6),;(7),,,4,5]1:(1);(2);(3);(4);(5)1.1194200012CHINESEJOURNALOFBIOMEDICALENGINEERINGVol.19No.4December20003(963607811):2000204214[69],,,,,,,,[10],muramyldipeptidemuramyltipeptidecholesterol,AA,,[11]Chavany[12],,21200,Allemann[13]ZnPcF16(PLA)(PEG)PLA,,(AUC02168=227ugh/g),PEG,,,,,[14](POE),W/O/W(MTX),,POE,,,,,POE,,,[15],99MTc4+(AIMN),99MTc4+AIMN,ECT,AIMN,AIMN,,6065%,,AIMN,[16]1.2,,[17],20[18][19,20],,,,,Lobenberg[21],42419azidothymidine(AZT),AZT18,AZT,1.3,,,,,[22],,,Langer530%,566%[23],,,,CGP57813,,AUC2,t1/21361,1.7L/kg3.6L/kg[24]Kim[25](11)Eudragit(RL/RS),0.120.21m,,(Cmax),TmaxMRT,Eudragit,,,,,1.4,Stieneker[26],,10100,,,(100nm)PeyerKossovsky[27],,,,,Peyer,,1.5Damage[28],5244:,,5060%50,,20;,,,,,,45%,,PeyerJani[29],,50nm100nm,40%26%,,82Maincent[30],,162%,36%,22%,,,,,,1.6,,,Carteolol,Carteolol,,metipranololZimmer[31],,,,,AUC,,;,Calvo,A2,,,,,CFTR,10%,,,[32]62419,,;,;Chavany[33],,,,,DNA,Truong[34],DNA,98%DNADNADNA,DNA,CFTRDNA,50%CFTRCFTR,CFTRGodard[35],,,T24,Ha2rasmRNA,,T24,Nakada33P2pdT16,,5,pdT16,,pdT163,()(),,,,:(1);(2),;(3),,;(4);(5),,,,MichiganLevy,:,,/,U286893(PLGA),PLGAPLGA,,,7244:,,U286893,,[36],,2,,,,,,,200800nm,,[37],Kreuter[38](280),,,,DalarginDalargin,,,Dalargin80(Polysorbate80),,,Alyautdin,80,loperamide,,4,,,,,,,,5m,:,,MPeyer,[39],,,,,,DNA,,,DNA,,,82419,[40]51SchwarzC,MehnertW.Solidliquidnanoparticles(SLN)forcontrolleddrugdeliveryII.Drugincorporationandphysicochemicalcharacterization.J.Microencapsulation,1999,16(2):2052132DominiqueDuchene,GillesPonchel,DenisWouessidjewe.Cyclodextrinsintargetingapplicationtonanoparti2cles.Adv.DrugDelve.Rev.1999,36:29403SongCX,LabhasetwarV,MurohyH,etal.Formulationandcharacterizationofbiodegradablenanoparticlesforintravascularlocaldrugdelivery.JControlRel,1997,43:1972124HincalA,Atilla,KasH.Suheyla.Recentadvancesinnanoparticlesandnanospheres.Biomed.Sci.Technol.[Proc.Int.Symp,4th,MeetingDate],1997,31395Cristiano,RichardJ.Targeted,non2viralgenedeliveryforcancergenetherapy.Front.Biosci,1998,3,D1161D11706BennisS,RobertJ,NematiF,etal.Enhancedtoxicityofdoxorubicinencapsulatedinpolyiso2hexylcyanoacrylatenanospheresagainstmultidrug2resistanttumoralcellsinculture.CancerRes.1992,33,A28467CouvreurC,Roblot2TreupelL,PouponMF,etal.Nanoparticlesasmicrocarriersforanticancerdrugs.Adv.DrugDelve.Rev.1990,5:2092308HuYP,ToulmeN,BennisS,etal.Doxorubicinencapsulationinlipsomesandnanospheresforthereversalofmultidrugresistanceinvitro.AnticancerDrugs,1994,37389KreuterJ.Poly(alkylacrylate)nanoparticle.MethodsEnzymol.1985,112:12913810MorinC,BarrattG,FessiH,etal.Improvedintracellulardeliveryofamuramyldipeptideanalogbymeansofnanocapsules.IntJImmunopharmacol.1994,16:45145611GodardG,BoutorrineAS,SaisonBE,etal.Antisenseeffectsofcholesterol2oligodeoxynucleotideconjugatesassociatedwithpoly(alkylcyanoacrylate)nanoparticles.Eur.J.Biochem.1995,232,40441012ChavanyC,SaisonBT,LeDT,etal.Adsorptionofoligonucleotidesontopolyisohexylcyanoacrylatenanoparti2clesprotectsthemagainstnucleasesandincreasestheircellularuptake.Pharm.Res.1996,11,1370137813AllemannE,BrasseurN,BenrezzakO,etal.PEG2coatedpoly(lacticacid)nanoparticlesforthedeliveryofhexadecafluorozincphthalocyaninetoEMT2Tmousemammarytumours.JPharmPharmzcol,1995,47(5):38238714SharmaD,ChelviTP,KaurJ,etal.NovelTaxolformulationpolyvinyplyrrolidonenanoparticle2encapsulatedTaxolfordrugdeliveryincancertherapy.OncolRes,1996,8:28228615,,..,1999,18(2):21622116..,1996,15(4):21622117Pinto2AlphandraryH,BallandO,CouvreurP,etal.Intracellularvisualizationofampicillin2loadednanoparti2clesinperitonealmacrophagesinfectedinvitrowithSalmonellatyphimurium.Pharm.Res.1994,11,384618FattalE,RojasJ,RolotTL,etal.Ampicillin2loadedlipsomesandnanoparticles:comparisonofdrugloading,drugreleaseandinvitroantimicrobialactivity.J.Microencapsulation.1991,8,293619SchaferV,vonBH,Rubsamen,WH,etal.Phagocytosisanddegradationofhumanserumalbuminmicro2spheresandnanoparticlesinhumanmacrophages.JMicroencapsulation,1994,11,26126920SchaferV,vonBH,BenderA,etal.InhibitionofHIVinfectioninvitrobyantiviraldrugtargetingusing9244:nanoparticles.Int.Conf.Aids,1993,9,229,no.Po2A252056521LobenbergR,KreuterJ.Macrophagetargetingofazidothymidine:apromisingstrategyforAIDStherapy.AIDSResHumRetroviruses.1996,12(18):1709171522StolnikS,DunnSE,IllumL,etal.Surfacemodificationofpoly(lactide2co2glycolide)nanospheresbybiodegradablepolylactide2poly(ethyleneglycol)copolymers.Pharm.Res.1994,11,1800180823GrefR,MinamitakeY,PeracchiaMT,etal.Biodegradablelongcirculatingpolymericnanospheres.Science,1994,263,1600160324LerouxJC,CozensR,RoeselJL,etal.PharmacokineticsofanovelHIV2Iproteaseinhibitorincorporatedintobiodegradableorentericnanoparticlesfollowingintravenousandoraladministrationtomice.JPharmSci,1995,84(12):1387139125KimYI,FluckigerL,HoffmanM,etal.Theantihypertensiveeffectoforallyadministerednifedipineloadednanoparticlesinspontaneouslyhypertensiverats.BrJPharmacol,1997,120(3):39940426StienekerF,KreuterJ,LowerJ.Highantibodytit